These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28761815)

  • 1. A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease.
    Lim HH; Yi H; Kishimoto TK; Gao F; Sun B; Kishnani PS
    Mol Genet Metab Rep; 2017 Dec; 13():18-22. PubMed ID: 28761815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
    Desai AK; Kazi ZB; Bali DS; Kishnani PS
    Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation.
    Desai AK; Shrivastava G; Grant CL; Wang RY; Burt TD; Kishnani PS
    Front Immunol; 2024; 15():1360369. PubMed ID: 38524130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
    Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
    Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Kazi ZB; Desai AK; Troxler RB; Kronn D; Packman S; Sabbadini M; Rizzo WB; Scherer K; Abdul-Rahman O; Tanpaiboon P; Nampoothiri S; Gupta N; Feigenbaum A; Niyazov DM; Sherry L; Segel R; McVie-Wylie A; Sung C; Joseph AM; Richards S; Kishnani PS
    Genet Med; 2019 Apr; 21(4):887-895. PubMed ID: 30214072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
    Rairikar M; Kazi ZB; Desai A; Walters C; Rosenberg A; Kishnani PS
    Mol Genet Metab; 2017 Sep; 122(1-2):76-79. PubMed ID: 28648664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.
    Curelaru S; Desai AK; Fink D; Zehavi Y; Kishnani PS; Spiegel R
    Mol Genet Metab Rep; 2022 Sep; 32():100893. PubMed ID: 35813979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
    Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
    Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
    Front Immunol; 2020; 11():1727. PubMed ID: 32849613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRIM-Negative Pompe Disease Patients with Satisfactory Clinical Outcomes on Enzyme Replacement Therapy.
    Khallaf HHA; Propst J; Geffrard S; Botha E; Pervaiz MA
    JIMD Rep; 2013; 9():133-137. PubMed ID: 23430560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
    van Kooten HA; Ditters IAM; Hoogeveen-Westerveld M; Jacobs EH; van den Hout JMP; van Doorn PA; Pijnappel WWMP; van der Ploeg AT; van der Beek NAME
    Orphanet J Rare Dis; 2022 Feb; 17(1):31. PubMed ID: 35109913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
    Khanna R; Flanagan JJ; Feng J; Soska R; Frascella M; Pellegrino LJ; Lun Y; Guillen D; Lockhart DJ; Valenzano KJ
    PLoS One; 2012; 7(7):e40776. PubMed ID: 22815812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers.
    Stenger EO; Kazi Z; Lisi E; Gambello MJ; Kishnani P
    Mol Genet Metab Rep; 2015 Sep; 4():30-34. PubMed ID: 26167453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
    Kishnani PS; Goldenberg PC; DeArmey SL; Heller J; Benjamin D; Young S; Bali D; Smith SA; Li JS; Mandel H; Koeberl D; Rosenberg A; Chen YT
    Mol Genet Metab; 2010 Jan; 99(1):26-33. PubMed ID: 19775921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
    Zhu Y; Li X; McVie-Wylie A; Jiang C; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
    Biochem J; 2005 Aug; 389(Pt 3):619-28. PubMed ID: 15839836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
    De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
    Front Immunol; 2021; 12():636731. PubMed ID: 34220802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease.
    Sun B; Banugaria SG; Prater SN; Patel TT; Fredrickson K; Ringler DJ; de Fougerolles A; Rosenberg AS; Waldmann H; Kishnani PS
    Mol Genet Metab Rep; 2014; 1():446-450. PubMed ID: 27896120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.
    Sasaki K; Uchimura T; Inaba A; Otani M; Hanakawa J; Ito S
    Pediatr Nephrol; 2023 Mar; 38(3):921-925. PubMed ID: 35864224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.